Arlington Trust Co LLC Decreases Stake in Eli Lilly and Company (NYSE:LLY)

Arlington Trust Co LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,589 shares of the company’s stock after selling 39 shares during the period. Eli Lilly and Company comprises about 0.5% of Arlington Trust Co LLC’s portfolio, making the stock its 26th biggest position. Arlington Trust Co LLC’s holdings in Eli Lilly and Company were worth $2,294,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Greenwich Wealth Management LLC raised its stake in Eli Lilly and Company by 18.2% in the third quarter. Greenwich Wealth Management LLC now owns 2,847 shares of the company’s stock valued at $2,522,000 after buying an additional 439 shares in the last quarter. Invesco LLC increased its holdings in shares of Eli Lilly and Company by 0.4% in the 3rd quarter. Invesco LLC now owns 5,205 shares of the company’s stock valued at $4,611,000 after acquiring an additional 22 shares during the last quarter. AM Investment Strategies LLC raised its position in shares of Eli Lilly and Company by 9.1% during the 3rd quarter. AM Investment Strategies LLC now owns 371 shares of the company’s stock worth $328,000 after acquiring an additional 31 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Eli Lilly and Company by 12.2% during the third quarter. Farther Finance Advisors LLC now owns 13,973 shares of the company’s stock worth $12,379,000 after purchasing an additional 1,520 shares during the last quarter. Finally, Capital Advisors Inc. OK boosted its holdings in Eli Lilly and Company by 25.1% in the third quarter. Capital Advisors Inc. OK now owns 5,687 shares of the company’s stock valued at $5,039,000 after purchasing an additional 1,141 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $818.93 on Friday. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The company has a 50-day moving average price of $911.04 and a 200 day moving average price of $866.16. The company has a market cap of $777.43 billion, a P/E ratio of 88.53, a PEG ratio of 3.13 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. Research analysts predict that Eli Lilly and Company will post 13.23 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. Bank of America cut their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,009.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.